VOR
Vor Biopharma Inc.Company Information
- Company Name
- Vor Biopharma Inc.
- CIK
- CIK0001817229
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- VOR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- VOR
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-30
- Last sale
- 2026-07-16
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 4,190,578
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 48,564,619
- Shares outstanding
- 54,304,456
- Ownership
- 89.43%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 6.19%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 108 | 170 | 396 | 160 | 191 | 50 | 82 | 53 | 76 | 45 | 31 | 45 | ||||||
| Restricted Cash Equivalents Current | - | - | - | - | 2 | - | - | - | - | - | - | - | ||||||
| Marketable Securities Current | 358 | 322 | 59 | 10 | 10 | 10 | 10 | 10 | 10 | 63 | 106 | 115 | ||||||
| Prepaid Expense Current | 6 | 6 | 1 | 1 | 2 | 5 | 4 | 4 | 4 | 4 | 3 | 4 | ||||||
| Other Assets Current | 3 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | ||||||
| Assets Current | 475 | 501 | 458 | 172 | 205 | 65 | 97 | 67 | 90 | 112 | 141 | 164 | ||||||
| Restricted Cash Equivalents Noncurrent | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 0 | 0 | 6 | 7 | 7 | 8 | 9 | 10 | 11 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 3 | 0 | 34 | 35 | 36 | 38 | 39 | 40 | 41 | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 0 | 0 | 2 | 2 | 3 | 3 | 5 | 5 | 4 | ||||||
| Assets | 481 | 507 | 464 | 176 | 205 | 109 | 143 | 116 | 142 | 167 | 198 | 223 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 1 | 5 | 1 | 1 | 4 | 2 | 1 | 2 | 2 | 1 | 1 | ||||||
| Accrued Liabilities Current | 20 | 15 | 20 | 18 | 58 | 9 | 13 | 9 | 8 | 7 | 11 | 10 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Other Liabilities Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 25 | 16 | 25 | 19 | 59 | 17 | 19 | 14 | 14 | 13 | 16 | 15 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 3 | 3 | 0 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | ||||||
| Liabilities | 681 | 657 | 628 | 2,402 | 1,711 | 43 | 46 | 43 | 44 | 44 | 47 | 48 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,236 | 1,223 | 989 | 650 | 557 | 556 | 554 | 499 | 497 | 494 | 491 | 489 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,435 | -1,373 | -1,153 | -2,876 | -2,063 | -489 | -457 | -426 | -399 | -371 | -340 | -314 | ||||||
| Stockholders Equity | -200 | -150 | -164 | -2,225 | -1,506 | 66 | 97 | 73 | 98 | 123 | 151 | 175 | ||||||
| Liabilities And Stockholders Equity | 481 | 507 | 464 | 176 | 205 | 109 | 143 | 116 | 142 | 167 | 198 | 223 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 800 | 800 | 800 | 800 | 800 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 54 | 54 | 39 | 9 | 6 | 6 | 6 | 3 | 3 | 3 | 3 | 0 | ||||||
| Shares Outstanding | 54 | 54 | 39 | 9 | 6 | 6 | 6 | 3 | 3 | 3 | 3 | 0 | ||||||
| Stockholders Equity Note Stock Split Conversion Ratio1 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVor Biopharma Inc. (VOR) — SEC Financial Statements & Analysis
Vor Biopharma Inc. (VOR) is a biological products, (no diagnostic substances) company. Vor Biopharma Inc. trades on Nasdaq as: VOR. Vor Biopharma Inc. (VOR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Vor Biopharma Inc. carries a market cap of $999.75M, a P/E ratio of 1.59x, a P/B ratio of -4.99x, an enterprise value of $891.89M, and an EV/EBITDA multiple of -6.10x. On profitability, it posts a Return on Equity (ROE) of -73.60%, a Return on Assets (ROA) of 182.91%, and a Return on Invested Capital (ROIC) of -259.64%. Per share, it reports EPS of $11.56, diluted EPS of $11.56, free cash flow per share of $-2.59, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -137.72% year-over-year and EPS growth of -104.35% year-over-year. On the balance sheet, it maintains a current ratio of 19.15x, a quick ratio of 18.91x, working capital of $450.29M, a debt-to-equity ratio of -3.40x, a debt ratio of 1.42, free cash flow of $-140.81M (TTM), and net debt of $-107.86M. Figures sourced from SEC EDGAR.
- Market Cap
- $999.75M
- P/E TTM
- 1.59x
- EPS TTM
- $11.56
- P/B TTM
- -4.99x
- ROE TTM
- -73.60%
- ROA TTM
- 182.91%
- Debt To Equity
- -3.40x
- Free Cash Flow TTM
- $-140.81M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vor Biopharma Inc. in?
Vor Biopharma Inc. (VOR) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does VOR trade on?
Vor Biopharma Inc. (VOR) trades on the Nasdaq.
When was Vor Biopharma Inc. (VOR)'s most recent SEC filing?
Vor Biopharma Inc. (VOR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is VOR's market cap?
Vor Biopharma Inc. (VOR) has a market capitalization of $999.75M as of 2026-06-30.
What is VOR's P/E ratio?
Vor Biopharma Inc. (VOR)'s trailing twelve month P/E ratio is 1.59x as of 2026-06-30.
What is VOR's EPS (earnings per share)?
Vor Biopharma Inc. (VOR)'s trailing twelve month EPS is $11.56 as of 2026-06-30.
What is VOR's ROE (return on equity)?
Vor Biopharma Inc. (VOR)'s trailing twelve month Return on Equity (ROE) is -73.60% as of 2026-06-30.
What is VOR's ROA (return on assets)?
Vor Biopharma Inc. (VOR)'s trailing twelve month Return on Assets (ROA) is 182.91% as of 2026-06-30.
What is VOR's ROIC (return on invested capital)?
Vor Biopharma Inc. (VOR)'s trailing twelve month Return on Invested Capital (ROIC) is -259.64% as of 2025-03-31.
What is VOR's EV/EBITDA?
Vor Biopharma Inc. (VOR)'s trailing twelve month EV/EBITDA is -6.10x as of 2026-06-30.